IS6266A - Ísómerísk sambrædd pýrrólókarbazól og ísóindólón - Google Patents

Ísómerísk sambrædd pýrrólókarbazól og ísóindólón

Info

Publication number: IS6266A
Authority: IS; Iceland
Prior art keywords: isoindolone; fused pyrrolocarbazole; isomeric fused; directed; same
Prior art date: 1999-08-20

Application number

IS6266A

Other languages

English (en)

Other versions

IS2186B (is

Inventor

L. Hudkins Robert

Original Assignee

Cephalon, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-20

Filing date

2002-02-12

Publication date

2002-02-12

2002-02-12 Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.

2002-02-12 Publication of IS6266A publication Critical patent/IS6266A/is

2006-12-15 Publication of IS2186B publication Critical patent/IS2186B/is

Links

XTBAPWCYTNCZTO-UHFFFAOYSA-N 1H-isoindolone Natural products C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 title abstract 3
QNMMYUBZGLXCCK-UHFFFAOYSA-N pyrrolo[3,2-a]carbazole Chemical compound N1=C2C=CC=CC2=C2C1=C1C=CN=C1C=C2 QNMMYUBZGLXCCK-UHFFFAOYSA-N 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 2
238000009007 Diagnostic Kit Methods 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Pyrrole Compounds (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Indole Compounds (AREA)

IS6266A 1999-08-20 2002-02-12 Ísómerísk sambrædd pýrrólókarbasól og ísóindólón IS2186B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15036799P	1999-08-20	1999-08-20
US09/640,825 US6399780B1 (en)	1999-08-20	2000-08-17	Isomeric fused pyrrolocarbazoles and isoindolones
PCT/US2000/022724 WO2001014380A1 (en)	1999-08-20	2000-08-18	Isomeric fused pyrrolocarbazoles and isoindolones

Publications (2)

Publication Number	Publication Date
IS6266A true IS6266A (is)	2002-02-12
IS2186B IS2186B (is)	2006-12-15

Family

ID=26847579

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6266A IS2186B (is)	1999-08-20	2002-02-12	Ísómerísk sambrædd pýrrólókarbasól og ísóindólón

Country Status (26)

Country	Link
US (4)	US6399780B1 (is)
EP (1)	EP1206473B1 (is)
JP (1)	JP4776842B2 (is)
KR (1)	KR100756686B1 (is)
CN (1)	CN1370173A (is)
AT (1)	ATE280172T1 (is)
AU (1)	AU776475C (is)
BG (1)	BG65545B1 (is)
BR (1)	BR0013811A (is)
CA (1)	CA2381885C (is)
CZ (1)	CZ2002616A3 (is)
DE (1)	DE60015153T2 (is)
EA (1)	EA005920B1 (is)
ES (1)	ES2230140T3 (is)
HK (1)	HK1046904B (is)
HU (1)	HUP0202758A3 (is)
IL (2)	IL148180A0 (is)
IS (1)	IS2186B (is)
MX (1)	MXPA02001789A (is)
NO (1)	NO323375B1 (is)
NZ (1)	NZ517174A (is)
PL (1)	PL354180A1 (is)
PT (1)	PT1206473E (is)
SK (1)	SK286805B6 (is)
TR (1)	TR200200474T2 (is)
WO (1)	WO2001014380A1 (is)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6399780B1 (en) *	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) *	2000-05-09	2006-10-17	Cephalon, Inc.	Multicyclic compounds and the use thereof
US7018999B2 (en)	2001-05-16	2006-03-28	Cephalon, Inc.	Methods for the treatment and prevention of pain
ATE404550T1 (de) *	2001-09-21	2008-08-15	Smithkline Beecham Corp	Chemische verbindungen
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
UA80447C2 (en) *	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
ZA200502612B (en)	2002-10-08	2007-07-25	Rinat Neuroscience Corp	Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
WO2005000194A2 (en) *	2002-10-08	2005-01-06	Rinat Neuroscience Corp.	Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
US9498530B2 (en)	2002-12-24	2016-11-22	Rinat Neuroscience Corp.	Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
DK2270048T3 (en)	2002-12-24	2016-01-18	Rinat Neuroscience Corp	Anti-NGF antibodies and methods for their use
US7569364B2 (en) *	2002-12-24	2009-08-04	Pfizer Inc.	Anti-NGF antibodies and methods using same
BRPI0407375A (pt) *	2003-02-19	2006-02-07	Rinat Neuroscience Corp	Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
US7169802B2 (en)	2003-12-23	2007-01-30	Cephalon, Inc.	Fused pyrrolocarbazoles
EP3372614B1 (en)	2004-04-07	2022-06-08	Rinat Neuroscience Corp.	Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US20060058250A1 (en) *	2004-09-10	2006-03-16	Cephalon, Inc.	Methods of treating proliferative skin diseases using carbazole derivatives
WO2006034121A1 (en) *	2004-09-17	2006-03-30	Henry Ford Health System	Methods and compositions for use of angiogenesis inhibitors in the prevention and/or control of epilepsy
BRPI0606793A8 (pt)	2005-02-04	2018-03-13	Astrazeneca Ab	composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
ES2347172T3 (es) *	2005-02-16	2010-10-26	Astrazeneca Ab	Compuestos quimicos.
SI1853588T1 (sl) *	2005-02-16	2008-10-31	Astrazeneca Ab	Kemične spojine
US20080287437A1 (en) *	2005-05-16	2008-11-20	Astrazeneca Ab	Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
JP2009513615A (ja)	2005-10-28	2009-04-02	アストラゼネカアクチボラグ	癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
JP5182088B2 (ja)	2006-04-19	2013-04-10	アステラス製薬株式会社	アゾールカルボキサミド誘導体
US20080021013A1 (en) *	2006-07-21	2008-01-24	Cephalon, Inc.	JAK inhibitors for treatment of myeloproliferative disorders
JP2010500961A (ja) *	2006-08-02	2010-01-14	武田薬品工業株式会社	α−カルボリン誘導体およびその製造方法
CA2668744C (en) *	2006-11-17	2015-09-15	Queen's University At Kingston	Compounds and methods for treating protein folding disorders
WO2010131855A2 (ko)	2009-05-13	2010-11-18	덕산하이메탈(주)	오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
JP2010524911A (ja) *	2007-04-18	2010-07-22	アストラゼネカアクチボラグ	５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
WO2008135786A1 (en) *	2007-05-04	2008-11-13	Astrazeneca Ab	Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2206707B1 (en)	2007-10-24	2014-07-23	Astellas Pharma Inc.	Azolecarboxamide compound or salt thereof
WO2009088054A1 (ja)	2008-01-11	2009-07-16	Astellas Pharma Inc.	精巣の疼痛又は不快感行動及び頻尿併発モデル動物
KR20110017445A (ko) *	2008-06-11	2011-02-21	아스트라제네카 아베	암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
BRPI0919488A2 (pt) *	2008-09-30	2015-12-01	Astrazeneca Ab	composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
CA2742790C (en)	2008-11-19	2018-02-13	Cephalon, Inc.	Novel forms of an indazolo[5,4-a]pyrrolo [3,4-c] carbazole compound
CN102482279B (zh) *	2009-03-30	2015-08-12	德山新勒克斯	有机电子装置及其化合物与终端机
WO2012024650A2 (en)	2010-08-19	2012-02-23	Abbott Laboratories	Anti-ngf antibodies and their use
KR101497122B1 (ko) *	2011-08-09	2015-03-06	덕산네오룩스 주식회사	2개 이상의 오원자 헤테로고리를 포함하는 화합물 및 이를 이용한 유기전기소자, 그 단말
TWI585088B (zh)	2012-06-04	2017-06-01	第一三共股份有限公司	作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
CA2875783C (en)	2012-06-06	2018-12-11	Zoetis Llc	Caninized anti-ngf antibodies and methods thereof
KR101478884B1 (ko)	2012-12-24	2015-01-05	충남대학교산학협력단	비스인돌일말레이미드계 화합물 및 이의 제조방법
MX2020004536A (es)	2017-11-23	2020-08-03	Biomed X Gmbh	Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
BR112020017701A2 (pt)	2018-03-12	2020-12-29	Zoetis Services Llc	Anticorpos anti-ngf e métodos dos mesmos

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816450A (en)	1986-09-15	1989-03-28	Duke University	Inhibition of protein kinase C by long-chain bases
US4735939A (en)	1987-02-27	1988-04-05	The Dow Chemical Company	Insecticidal activity of staurosporine
US4923986A (en)	1987-03-09	1990-05-08	Kyowa Hakko Kogyo Co., Ltd.	Derivatives of physiologically active substance K-252
JPH07113027B2 (ja)	1987-12-24	1995-12-06	協和醗酵工業株式会社	Ｋ−２５２誘導体
FR2631199B1 (fr)	1988-05-09	1991-03-15	Centre Nat Rech Scient	Reacteur a plasma
US5621101A (en)	1992-07-24	1997-04-15	Cephalon, Inc.	Protein kinase inhibitors for treatment of neurological disorders
AU679752B2 (en)	1993-05-28	1997-07-10	Cephalon, Inc.	Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5624949A (en)	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
CA2179650C (en)	1993-12-23	2007-10-30	William Francis Heath, Jr.	Bisindolemaleimides and their use as protein kinase c inhibitors
US5545636A (en)	1993-12-23	1996-08-13	Eli Lilly And Company	Protein kinase C inhibitors
GB9416467D0 (en) *	1994-08-13	1994-10-05	Wellcome Found	Compounds for use in medicine
US5705511A (en) *	1994-10-14	1998-01-06	Cephalon, Inc.	Fused pyrrolocarbazoles
US5591855A (en) *	1994-10-14	1997-01-07	Cephalon, Inc.	Fused pyrrolocarbazoles
US5475110A (en) *	1994-10-14	1995-12-12	Cephalon, Inc.	Fused Pyrrolocarbazoles
US5594009A (en) *	1994-10-14	1997-01-14	Cephalon, Inc.	Fused pyrrolocarbazoles
SI0776895T1 (en)	1995-11-20	1999-04-30	Eli Lilly And Company	Protein kinase C inhibitor
US5808060A (en) *	1995-12-11	1998-09-15	Cephalon, Inc.	Fused isoindolones
US5616724A (en)	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
NZ333536A (en)	1996-08-22	1999-10-28	Bristol Myers Squibb Co	Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles, and use as antitumour agents
US6399780B1 (en) *	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones

2000
- 2000-08-17 US US09/640,825 patent/US6399780B1/en not_active Expired - Lifetime
- 2000-08-18 DE DE60015153T patent/DE60015153T2/de not_active Expired - Lifetime
- 2000-08-18 MX MXPA02001789A patent/MXPA02001789A/es active IP Right Grant
- 2000-08-18 AT AT00954136T patent/ATE280172T1/de active
- 2000-08-18 ES ES00954136T patent/ES2230140T3/es not_active Expired - Lifetime
- 2000-08-18 PT PT00954136T patent/PT1206473E/pt unknown
- 2000-08-18 WO PCT/US2000/022724 patent/WO2001014380A1/en not_active Ceased
- 2000-08-18 CA CA002381885A patent/CA2381885C/en not_active Expired - Fee Related
- 2000-08-18 IL IL14818000A patent/IL148180A0/xx active IP Right Grant
- 2000-08-18 AU AU66471/00A patent/AU776475C/en not_active Ceased
- 2000-08-18 PL PL00354180A patent/PL354180A1/xx unknown
- 2000-08-18 HU HU0202758A patent/HUP0202758A3/hu unknown
- 2000-08-18 EP EP00954136A patent/EP1206473B1/en not_active Expired - Lifetime
- 2000-08-18 NZ NZ517174A patent/NZ517174A/en unknown
- 2000-08-18 EA EA200200271A patent/EA005920B1/ru not_active IP Right Cessation
- 2000-08-18 KR KR1020027002117A patent/KR100756686B1/ko not_active Expired - Fee Related
- 2000-08-18 CN CN00811850A patent/CN1370173A/zh active Pending
- 2000-08-18 BR BR0013811-8A patent/BR0013811A/pt not_active Application Discontinuation
- 2000-08-18 CZ CZ2002616A patent/CZ2002616A3/cs unknown
- 2000-08-18 SK SK246-2002A patent/SK286805B6/sk not_active IP Right Cessation
- 2000-08-18 TR TR2002/00474T patent/TR200200474T2/xx unknown
- 2000-08-18 HK HK02108409.6A patent/HK1046904B/en not_active IP Right Cessation
- 2000-08-18 JP JP2001518711A patent/JP4776842B2/ja not_active Expired - Fee Related
2002
- 2002-02-01 US US10/062,159 patent/US6635669B2/en not_active Expired - Lifetime
- 2002-02-12 IS IS6266A patent/IS2186B/is unknown
- 2002-02-14 IL IL148180A patent/IL148180A/en not_active IP Right Cessation
- 2002-02-19 NO NO20020809A patent/NO323375B1/no not_active IP Right Cessation
- 2002-02-21 BG BG106423A patent/BG65545B1/bg unknown
2003
- 2003-04-24 US US10/422,164 patent/US6872746B2/en not_active Expired - Fee Related
2005
- 2005-01-05 US US11/029,330 patent/US7291732B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20020038730A (ko)	2002-05-23
WO2001014380A1 (en)	2001-03-01
NZ517174A (en)	2003-09-26
EA200200271A1 (ru)	2002-08-29
KR100756686B1 (ko)	2007-09-07
SK2462002A3 (en)	2002-12-03
NO20020809D0 (no)	2002-02-19
DE60015153T2 (de)	2006-02-09
US6635669B2 (en)	2003-10-21
BG65545B1 (bg)	2008-11-28
BR0013811A (pt)	2002-07-23
CA2381885A1 (en)	2001-03-01
IS2186B (is)	2006-12-15
CA2381885C (en)	2009-10-27
NO20020809L (no)	2002-02-20
IL148180A (en)	2008-04-13
TR200200474T2 (tr)	2002-06-21
BG106423A (en)	2002-09-30
AU776475B2 (en)	2004-09-09
AU6647100A (en)	2001-03-19
HK1046904A1 (en)	2003-01-30
IL148180A0 (en)	2002-09-12
US7291732B2 (en)	2007-11-06
US6872746B2 (en)	2005-03-29
ATE280172T1 (de)	2004-11-15
EP1206473B1 (en)	2004-10-20
US20020147341A1 (en)	2002-10-10
SK286805B6 (sk)	2009-05-07
DE60015153D1 (de)	2004-11-25
JP4776842B2 (ja)	2011-09-21
EP1206473A1 (en)	2002-05-22
HK1046904B (en)	2005-05-06
US20030216419A1 (en)	2003-11-20
MXPA02001789A (es)	2003-07-14
PL354180A1 (en)	2003-12-29
ES2230140T3 (es)	2005-05-01
JP2003507480A (ja)	2003-02-25
EA005920B1 (ru)	2005-08-25
CZ2002616A3 (cs)	2003-04-16
CN1370173A (zh)	2002-09-18
HUP0202758A3 (en)	2004-12-28
US20050107458A1 (en)	2005-05-19
AU776475C (en)	2005-04-07
HUP0202758A2 (hu)	2002-12-28
US6399780B1 (en)	2002-06-04
NO323375B1 (no)	2007-04-16
PT1206473E (pt)	2005-01-31

Publication	Publication Date	Title
IS2186B (is)	2006-12-15	Ísómerísk sambrædd pýrrólókarbasól og ísóindólón
MXPA02004415A (es)	2004-09-10	Pirazolonas sustituidas con heterociclicas.
EA200100589A1 (ru)	2002-02-28	Азабициклоалканы как модуляторы ccr5
HUP0203567A2 (hu)	2003-02-28	APRIL-receptor (BCMA) és alkalmazásai
EA200100588A1 (ru)	2002-02-28	Пиперидины как модуляторы ccr5
BG66084B1 (bg)	2011-03-31	Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ES2195163T3 (es)	2003-12-01	Derivados de pirimidina biciclicos y su uso como anticoagulantes.
FI964520L (fi)	1996-11-11	Atsabisykloyhdisteet
DE69919700D1 (de)	2004-09-30	Überbrückte indenopyrrolocarbazole
EA200100887A1 (ru)	2002-02-28	Циклические замещенные конденсированные пирролкарбазолы и изоиндолоны
ATE365740T1 (de)	2007-07-15	Substituierte pyrazolopyrimidine
EE05091B1 (et)	2008-10-15	Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
MY158159A (en)	2016-09-15	Novel fused pyrrolocarbazoles
TR200002380T2 (tr)	2001-03-21	Yeni triazolo (4,5-d) pirimidin bileşikleri
YU62504A (sh)	2006-08-17	Triciklična 2-pirimidonska jedinjenja korisna kao inhibitori hiv reverzne transkriptoze
EE200200326A (et)	2003-10-15	Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
ES2195033T3 (es)	2003-12-01	Iso-indolonas condensadas utilizadas como inhibidores de proteina quinasa c.
EA199700223A1 (ru)	1998-04-30	Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
EA200200981A1 (ru)	2003-02-27	Антагонисты рецептора il-8
DE60106947D1 (de)	2004-12-09	Oxindolderivate
EE9900188A (et)	1999-12-15	HIV proteaasi inhibiitoritena kasulikud 1-(3-aminoindasool-5-üül)-3-fenüülmetüül-tsüklilised uuread